Articles By Anuja Singh
Is Roche’s $480M Bet Making South Korea Asia’s Next Biopharma Powerhouse?
Roche’s $480M Bet on South Korea Signals a Strategic Pivot to Asia’s AI–Oncology Powerhouse Roche has committed $480 million to…
ByPepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline…
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines PepGen’s experimental Duchenne…
Blackstone’s $400M Bet on Teva–Sanofi Gut Drug Signals a Major Shift in the IBD…
Blackstone has invested $400 million into Teva and Sanofi’s experimental ulcerative colitis (UC) and Crohn’s disease therapy, marking one of…
Has China Now Overtaken the US at the Heart of Biotech Innovation?
Recent data from JPM2026 shows that China has surpassed the United States in key biotech activity measures—topping the…
Is Hong Kong Becoming Asia’s AI–Biopharma Hub?
Hong Kong is emerging as a key AI‑biopharma hub, with recent deals like Earendil Labs’ partnership with Sanofi…
Is Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?
Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a major expansion of…
Is Roche’s $480M Bet Making South Korea Asia’s Next Biopharma Powerhouse?
Roche’s $480M Bet on South Korea Signals a Strategic Pivot to Asia’s AI–Oncology Powerhouse Roche has committed $480 million to…
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline…
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines PepGen’s experimental Duchenne…
Blackstone’s $400M Bet on Teva–Sanofi Gut Drug Signals a Major Shift in the IBD…
Blackstone has invested $400 million into Teva and Sanofi’s experimental ulcerative colitis (UC) and Crohn’s disease therapy, marking one of…
Has China Now Overtaken the US at the Heart of Biotech Innovation?
Recent data from JPM2026 shows that China has surpassed the United States in key biotech activity measures—topping the…
Is Hong Kong Becoming Asia’s AI–Biopharma Hub?
Hong Kong is emerging as a key AI‑biopharma hub, with recent deals like Earendil Labs’ partnership with Sanofi…
Is Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?
Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a major expansion of…